

PEVONEDISTAT (TAK-924): A POTENTIAL NEW TREATMENT FOR HR-MDS AND AML




Phil Rowlands, PhD

Head Oncology Therapeutic Area Unit Takeda Pharmaceutical Company Limited New York, NY November 14, 2019

Better Health, Brighter Future

BUILDING ON THE TAKEDA ONCOLOGY FOUNDATION IN HEMATOLOGIC MALIGNANCIES






HIGH RISK MYELODYSPLASTIC SYNDROME (HR-MDS) AND ACUTE MYELOID LEUKEMIA (AML) HAVE LIMITED TREATMENT OPTIONS




CONTINUUM OF HR-MDS AND AML




- HR-MDS and AML are both rare bone marrowrelated cancers that share foundational biology, clinical features, and genetic mutations*
- Incidence highest in elderly (>70 years old)
- Overall survival several months to a few years, depending on risk category

CLINICAL TREATMENT





MDS SURVIVAL BY PROGNOSTIC RISK




Median survival ~6 months to 5 years

- No new treatments have been approved for MDS in over a decade
- Transplant ineligible patients treated with first line therapy: Median OS = 15mo; 2yr OS rate 35%
- Economic burden is substantial hospitalizations are common among patients and many are transfusion dependent

PEVONEDISTAT: A UNIQUE FIRST-IN-CLASS NAE INHIBITOR




- Pevonedistat is a small molecule inhibitor of NAE (NEDD-8 activating enzyme), a protein involved in the ubiquitin-proteasome system
- NAE acts upstream of the proteasome and catalyzes the first step in the neddylation pathway



ENCOURAGING RESPONSES IN AML PATIENTS TREATED WITH PEOVNEDISTAT + AZACITIDINE





60% ORR with a trend towards improved survival in secondary AML

Response rates not influenced by AML genetic risk or leukemia burden




Initial data drove interest to move to registration

A PHASE 2 STUDY IN HR-MDS TO CONFIRM THE RISK / BENEFIT PROFILE OBSERVED IN AML



Phase 2, Randomized, Open-label, Global, Multicenter Study Comparing Pevonedistat Plus Azacitidine vs. Azacitidine in Patients with Higher-Risk MDS, CMML, or Low-Blast AML




- Mature OS data will be available in November
- Data will be presented in upcoming congress
- Potential approval in FY21*

THE PHASE 3 PANTHER STUDY WAS INITIATED AT RISK TO ACCELERATE DEVELOPMENT



Phase 3, Randomized controlled trial of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients with Higher risk-MDS/CMML, or Low-blast AML





- Completed global enrollment 10 months earlier than originally projected*
- Indicative of demand for new innovative therapies

EXPANDING PATIENT-CENTRIC DEVELOPMENT OF PEVONEDISTAT





Ph2 (P2002) Combo

pevo + venetoclax + aza vs. venetoclax + aza Study will open in 2020 Unique MOA and biologic hypothesis to support combination

SUMMARY



1

Unmet need in Highrisk MDS and AML remain high with few treatment options

2

Pevonedistat is a selective first-in-class inhibitor with potential to be first new therapy in over a decade for HR-MDS

3

The Ph2 HR-MDS trial has reached the updated OS endpoint data readout and the PANTHER Ph3 trial has completed global enrollment

R&D DAY AGENDA – NEW YORK, NOVEMBER 14, 2019



TIME	AGENDA
12:30 – 12:35	Welcome and Opening Remarks Sheelagh Cawley-Knopf, Head R&D Global Portfolio Strategy
12:35 – 12:45	Takeda: A Global Values-Based, R&D-Driven Biopharmaceutical Leader Christophe Weber, President & CEO Takeda
12:45 – 13:20	Translating Science into Highly Innovative, Life-changing Medicines Andy Plump, President R&D
13:20 – 13:45	Oncology and Cell Therapies with Spotlight on CAR-NK Chris Arendt, Head Oncology Drug Discovery Unit
13:45 – 14:05	Spotlight on Oncology Opportunities TAK-788 : Rachael Brake, Global Program Lead Pevonedistat : Phil Rowlands, Head Oncology Therapeutic Area Unit
14:05 – 14:20	Break
14:20 – 14:45	Rare Diseases & Gene Therapy Dan Curran, Head Rare Disease Therapeutic Area Unit
14:45 – 15:00	Spotlight on Orexin2R agonists Deborah Hartman, Global Program Lead
15:00 - 15:20	Therapeutic Area Focus in GI with Spotlight on Celiac Disease Asit Parikh, Head GI Therapeutic Area Unit
15:20 - 16:00	Panel Q&A Session
16:00	Drinks reception




RARE DISEASES & GENE THERAPY



Dan Curran, MD Head Rare Diseases Therapeutic Area Unit Takeda Pharmaceutical Company Limited New York, NY November 14, 2019

Better Health, Brighter Future






1. Rare diseases defined by prevalence in line with regulatory agencies (US: <7 in 10,000, EU: <5 in 10,000 and JPN: <4 in 10,000), Global Genes, NIH National Human Genome Research Institute; 2. Comprises four pathways in US: Accelerated approval, breakthrough therapy designation, fast track designation, priority review designation; 3. Three pathways in JPN: Priority review, Sakigake designation and conditional approval, CIRS R&D Briefing 70, New drug approvals in six major authorities 2009-2018

RARE DISEASE MARKET IS EXPECTED TO DOUBLE IN SIZE



GLOBAL ORPHAN DRUG¹ SALES EXCLUDING ONCOLOGY², USD BN



- Orphan drugs expected to make up ~17% of global branded Rx sales by 2024
- Growth driven by advances in new modalities and new indications
- Orphan cell and gene therapies estimated at ~\$20 bn by 2024, up from ~\$2bn in 2018

TAKEDA IS THE LEADER IN RARE DISEASES



PATIENT IMPACT



- Foundation of >30 year history of leadership in rare diseases
- Leading portfolio of rare disease therapies: 11 out of 14 global brands spanning Hematology, Metabolic, GI and Immunology

SCIENCE & INNOVATION



- Multiple opportunities for transformational therapies across therapeutic areas
- Emerging, cutting edge platforms to drive high-impact pipeline
- Investments in technologies to accelerate diagnosis

CAPABILITIES AND SCALE



- Engagement with key stakeholders within the ecosystem e.g. patient groups, regulators
- Pioneering regulatory pathways
- Global footprint




As the global leader in Rare Diseases, we aspire to provide transformative and curative treatments to our patients

Transformative

Curative

Programs with transformative potential in devastating disorders with limited or no treatment options today Emerging early pipeline of AAV gene therapies to redefine treatment paradigm in monogenic rare diseases

WE ARE POSITIONED TO DELIVER NEAR-TERM & SUSTAINED GROWTH Takeda



1. Projected timing of approvals depending on data read-outs; some of these Wave 1 target approval dates assume accelerated approval; 2. Some Wave 2 assets could be accelerated into Wave 1 if they have breakthrough data; 3. Projected approval date assumes filing on Phase 2 data; 4. TAK-079 to be developed in Rare Diseases indications myasthenia gravis (MG) and immune thrombocytopenic purpura (ITP) (FPI projected in each indication in 2H FY19); 5. Currently in a non-pivotal Phase 2 study; planning underway to include interim stage gates that can advance the program into a pivotal trial

Orphan potential in at least one indication Estimated dates as of November 14, 2019

POTENTIAL APPROVALS OF TRANSFORMATIVE THERAPIES



WAVE 1¹ Phase 3 Phase 2 Phase 2 Phase 1/2 Phase 3 Phase 3 Phase 2b Orexin **TAK-611 TAK-721 TAK-620 TAK-755 TAK-935 TAK-607** Narcolepsy Type 1 **Complications of** Eosinophilic **Cytomegalovirus** Metachromatic Developmental Congenital (NT1) Thrombotic Esophagitis (CMV) infection Leukodystrophy and Epileptic Prematuritv² (EoE) in transplant Thrombocytopenic (MLD) Encephalopathies Purpura (cTTP) (DEE) **TARGET APPROVAL** POSSIBLE WAVE 1 **FY 2020** FY 2021 FY 2023 FY 2023 FY 2023 FY 2024 APPROVAL² ADDRESSABLE POPULATION IN US/WW^{3,4} 70 - 140k/ ~150k/Under ~500/ ~350/ ~50k/ ~25k/ ~7 - 15k/ 300k - 1.2M evaluation ~70 - 90k ~80 - 90k ~25 - 45k 2 - 6k ~1 - 2k

1. Projected timing of approvals depending on data read-outs; some Wave 1 target approval dates assume accelerated approval

2. Currently in a non-pivotal Phase 2 study; planning underway to include interim stage gates that can advance the program into a pivotal trial

3. Estimated number of patients projected to be eligible for treatment, in markets where the product is anticipated to be commercialized, subject to regulatory approval

4. For TAK-620 and TAK-607, the addressable population represents annual incidence



TAK-620	Potential first treatment of CMV infection in transplant patients in over 10 years. Inhibitor of protein kinase UL97.	
TAK-755	Potential best-in-class therapy for Thrombotic Thrombocytopenic Purpura (TTP). Recombinant ADAMTS13.	
TAK-607	Potential first pharmacologic therapy in >20 years to prevent complications of prematurity. Recombinant IGF-1 growth factor.	

TAK-620: POTENTIAL BEST IN CLASS TREATMENT FOR POST-TRANSPLANT CMV INFECTION



BURDEN OF CMV INFECTION IN TRANSPLANT RECIPIENTS

CMV infection is the most common post-transplant viral infection¹

Affects >25% of transplants


CMV infection can be fatal^{2,3}

Higher rates of graft failure: 2.3X and mortality: 2.6X

Current therapies have significant toxicities and resistance^{4,5,6,7}

Incidence of neutropenia >20% and renal toxicity >50%


TAK-620: NOVEL MOA TARGETING PROTEIN KINASE UL97



^{1.} Minerva Med. 2009 Dec; 100(6): 479-501; 2. Blood. 2016 May 19;127(20):2427-38; 3. Infect Chemother. 2013 Sep; 45(3): 260–271; 4. Antimicrob Agents Chemother. 2014 Jan; 58(1): 128–135; 5. Transplantation. 2016 Oct;100(10):e74-80;. 6. Clin Microbiol Infect. 2015 Dec;21(12):1121.e9-15; 7. Clin Transplant 2009: 23: 295–304

TAK-620: ADDRESSES UNMET NEED IN BOTH FIRST-LINE AND RESISTANT / REFRACTORY SETTING







TAK-620 DEMONSTRATED SIMILAR EFFICACY AND BETTER SAFETY VERSUS SOC IN A PHASE 2 STUDY IN FIRST-LINE PATIENTS



The NEW ENGLAND JOURNAL of MEDICINE
ORIGINAL ARTICLE
Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation
Johan Maertens, M.D., Catherine Cordonnier, M.D., Peter Jaksch, M.D.,

Xavier Poiré, M.D., Marc Uknis, M.D., Jingyang Wu, M.S., Anna Wijatyk, M.D., Faouzi Saliba, M.D., Oliver Witzke, M.D., and Stephen Villano, M.D.

DEMONSTRATED SIMILAR ANTI-VIRAL ACTIVITY TO VALGANCICLOVIR (VGV) ACROSS ALL DOSES¹

NEUTROPENIA WAS TREATED WITH GROWTH FACTORS MORE OFTEN IN THE VGV ARM (15%) VS. TAK-620 ARM (7%)²

	TAK-620: Dose 400, 800 or 1200 mg BID ² All Doses (N=119)	VGV (N=40)	
Confirmed undetectable plasma CMV DNA within 6 weeks	79%	67%	

TAK-620:
Dose 400, 800 or 1200 mg BIDVGV
(N=40)All Doses (N=119)Neutropenia that
occurred or worsened
during treatment
through week 1218%

1. Confirmed undetectable CMV DNA in plasma was defined as two consecutive CMV DNA polymerase-chain-reaction assay values measure during treatment that were below the level of quantitation (i.e., <200 copies per millimeter according to the central laboratory) separated by at least 5 days. For the primary analyses of confirmed undetectable CMV DNA within 3 weeks and 6 weeks, data were missing for 3 patients: 1 each in the 400-mg TAK-620 group, the 1200-mg TAK-620 group and the valganciclovir group

2. N Engl J Med 2019; 381:1136-47. Overall risk ratio (95% CI) relative to the Valganciclovir reference was 1.20 (0.95-1.51)

TAK-620: GRANTED BREAKTHROUGH DESIGNATION IN RESISTANT OR REFRACTORY CMV INFECTION



1

Efficacy in seriously ill R/R CMV in SOT and HSCT recipients with multiple risk factors predictive of poor outcomes

TAK-620 Dose: 400 mg, 800 mg, 1200 mg BID ¹	
Primary efficacy endpoint All doses (Total N = 120)	
Patients with confirmed undetectable plasma CMV DNA within 6 weeks in ITT ² population	80 (66.7%)

2

Superior renal safety profile - did not result in treatment discontinuations

Clinical Infectious Diseases



Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study

Genovefa A. Papanicolaou,¹ Fernanda P. Silveira,² Amelia A. Langston,³ Marcus R. Pereira,⁴ Robin K. Avery,⁵ Marc Uknis,⁶ Anna Wijatyk,⁷ Jingyang Wu,⁷ Michael Boeckh,⁹ Francisco M. Marty,³* and Stephen Villano^{6,4}

Historical outcomes: High (~50%) failure rates / relapse rates^{3,4,5}


Renal impairment is the primary reason for discontinuation with SOC (Foscarnet, Cidovir); nephrotoxicity is > 50%⁶

TAK-620: TWO ONGOING PIVOTAL STUDIES; EXPECT FIRST APPROVAL IN RESISTANT OR REFRACTORY CMV IN 2021



TAK-620 PHASE 3 STUDY 303

TAK-620 PHASE 3 STUDY 302





TAK-620	Potential first treatment of CMV infection in transplant patients in over 10 years. Inhibitor of protein kinase UL97.	
TAK-755	TAK-755Potential best-in-class therapy for Thrombotic Thrombocytopenic Purpura (TTP). Recombinant ADAMTS13.	
TAK-607	Potential first pharmacologic therapy in >20 years to prevent complications of prematurity. Recombinant IGF-1 growth factor.	

CONGENITAL AND IMMUNE TTP HAVE SUBSTANTIAL MORTALITY AND MORBIDITY BURDEN DUE TO INADEQUATE SOC



CONGENITAL TTP (cTTP)

- Sub-therapeutic dose with plasma infusions
- Patients still experience ischemic injury of brain, kidneys and heart
- Poor long-term outcomes

IMMUNE TTP (iTTP)

- ~30% relapse rate with plasma exchange (PEX)
- New market entrant reduces relapse rate, but has significant limitations^{3,4}
 - Enhanced risk of bleeding:
 Gingival bleeding 18% vs. 1% placebo
 Epistaxis 32% vs. 3% placebo




ADDRESSABLE POPULATION (WW) ^{1,2}		
cTTP	2,000 - 6,000	
iTTP	5,000 - 18,000	

TAK-755 DIRECTLY ADDRESSES UNDERLYING CAUSE OF TTP




TAK-755 REPLACES ADAMTS13, DEFICIENCY OF WHICH LEADS TO TTP



ADAMTS13 deficiency:

TTP

Formation of microthrombi due to accumulation of large VWF multimers




TAK-755: POTENTIAL TRANSFORMATIVE THERAPY FOR TTP



TAK-755 PHASE I, OPEN-LABEL, DOSE ESCALATION STUDY IN cTTP¹

TAK-755 PK PROFILE AND PD EFFECT ON VWF CLEAVAGE AT 40 IU/KG


- Administered as a single dose in 15 cTTP patients
- TAK-755 was well tolerated
- No anti-ADAMTS13 antibodies detected



TAK-755: ONGOING PHASE 3 CONGENITAL TTP STUDY




TAK-755 PHASE 3 PROPHYLAXIS STUDY



TAK-755 IMMUNE TTP PHASE 2 STUDY DESIGN








TAK-620	Potential first treatment of CMV infection in transplant patients in over 10 years. Inhibitor of protein kinase UL97.
TAV 755	Potential best-in-class therapy for Thrombotic Thrombocytopenic Purpura (TTP).
TAK-755	Recombinant ADAMTS13.
TAK-607Potential first pharmacologic therapy in >20 years to prevent complications of prematurity. Recombinant IGF-1 growth factor.	

EXTREMELY PREMATURE INFANTS EXPERIENCE CONSIDERABLE MORBIDITY





Morbidity (%) by birth year, US data¹





X

~80,000-90,000 Extremely preterm babies (<28 wks gestational age) born WW^{2,3}

~40% have lung
 complications

in addition to morbidities in brain, eye that adversely impact development and learning



0 Therapies

for prevention of complications of prematurity



~\$200,000
hospitalization
costs per infant 4

TAK-607 REPLENISHES IGF-1, A FETAL GROWTH FACTOR THAT IS DECREASED IN PRETERM INFANTS




TAK-607: IGF-1 / IGFBP-3¹COMPLEX

• IGF-1 is an important fetal growth factor supplied by the mother that is involved in the development of multiple organs

- IGF-1 is low or absent in premature infants born before 28 weeks²
- TAK-607 demonstrated beneficial effects in lung development and brain vasculature in preclinical models^{3,4}

IGF-1 LEVELS ARE LOW IN PRETERM INFANTS²



TAK-607: PHASE 2 STUDY INFORMED DOSE AND ENDPOINT SELECTION



8%

IVH (Grade 3-4)

ROP-2008-01: RANDOMIZED, CONTROLLED PHASE 2 STUDY OF TAK-607 TAK-607 IMPACTED BPD AND IVH² 100 Pre-term infants with a gestational age (GA) <28 weeks (N = 120) Standard of care **IGF-1/IGFBP-3** • Assessed outcomes in ITT and "evaluable" sets (40% patients 80 Number of infants % who achieved target exposure of IGF-1 levels)¹ (evaluable set²) 60 55% • Primary endpoint: ROP not met 40 • Pre-specified secondary endpoints: Bronchopulmonary 29% 23% Dysplasia (BPD) was reduced and Intra-Ventricular 20

n

BPD (Moderate


and Severe)

• Granted FDA fast-track designation

Hemorrhage (IVH) showed a positive trend

TAK-607: FOOTPRINTS STUDY DESIGNED TO DEMONSTRATE REDUCTION IN THE COMPLICATIONS OF PREMATURITY






1. Supplemental oxygen use defined by one of the following: a) Any fraction of inspired oxygen (FiO2) >21%, b) Non-invasive respiratory support delivered via a nasal interface (e.g., continuous positive airway pressure [CPAP], nasal cannula, etc.), c) Invasive respiratory support (mechanical ventilation) via an endotracheal tube or tracheostomy

NME MILESTONES ACHIEVED IN FY19 AND LOOKING AHEAD TO OTHER POTENTIAL MILESTONES¹ THROUGH FY20



PIVOTAL STUDY STARTS, APPROVALS



Denotes milestones that have been achieved.

KEY DATA READOUTS

1. Potential key milestone dates as of November 14, 2019. The dates included herein are estimates based on current data and are subject to change 2. Potentially registration enabling



As the global leader in Rare Diseases, we aspire to provide transformative and curative treatments to our patients

Transformative

Curative

Programs with transformative potential in devastating disorders with limited or no treatment options today Emerging early pipeline of AAV gene therapies to redefine treatment paradigm in monogenic rare diseases


BUILDING A WORLD CLASS GENE THERAPY 'ENGINE'



TOP TIER GMP MANUFACTURING	GENE THERAPY AAV ¹ PLATFORM	GENE THERAPY PIPELINE
		TAKEDA THERAPEUTIC AREAS
	A	Preclinical Clinical Development Development
		Liver expression
	 Strong capabilities in liver expression Emerging capabilities in 	3+ Research CandidatesNextGen Hem ATAK-748 Hem BTAK-754 Hem A
		CNS expression
ELER A	CNS expression	StrideBioStrideBioResearchFriedreichCandidateAtaxia

WE WILL APPLY OUR CELL THERAPY PLAYBOOK AND UNIFYING CAPABILITIES TO BUILD A GENE THERAPY PIPELINE





SUMMARY



1

Takeda has the capabilities, scale, and innovative platforms to extend our leadership in Rare Diseases

2

We have a leading late stage portfolio of transformative programs that will establish or re-define the standard of care for highly underserved patients

3

We are building cutting edge capabilities in gene therapy that aim to deliver 'cures' in monogenic rare diseases

R&D DAY AGENDA – NEW YORK, NOVEMBER 14, 2019



TIME	AGENDA
12:30 – 12:35	Welcome and Opening Remarks Sheelagh Cawley-Knopf, Head R&D Global Portfolio Strategy
12:35 – 12:45	Takeda: A Global Values-Based, R&D-Driven Biopharmaceutical Leader Christophe Weber, President & CEO Takeda
12:45 – 13:20	Translating Science into Highly Innovative, Life-changing Medicines Andy Plump, President R&D
13:20 – 13:45	Oncology and Cell Therapies with Spotlight on CAR-NK Chris Arendt, Head Oncology Drug Discovery Unit
13:45 – 14:05	Spotlight on Oncology Opportunities TAK-788 : Rachael Brake, Global Program Lead Pevonedistat : Phil Rowlands, Head Oncology Therapeutic Area Unit
14:05 – 14:20	Break
14:20 – 14:45	Rare Diseases & Gene Therapy Dan Curran, Head Rare Disease Therapeutic Area Unit
14:45 – 15:00	Spotlight on Orexin2R agonists Deborah Hartman, Global Program Lead
15:00 – 15:20	Therapeutic Area Focus in GI with Spotlight on Celiac Disease Asit Parikh, Head GI Therapeutic Area Unit
15:20 – 16:00	Panel Q&A Session
16:00	Drinks reception